Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUKBI2)

• Drug Name: mRNA-2752 Drug Info
• Synonyms: mRNA-OX40L/IL-23/IL-36 gamma

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMUKBI2

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-23 (IL23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ustekinumab	DMHTYK3	Plaque psoriasis	EA90.0	Approved	[3]
Tildrakizumab	DMLW9HG	Plaque psoriasis	EA90.0	Approved	[4]
CNTO-1959	DMPC2QY	Plaque psoriasis	EA90.0	Approved	[5]
Risankizumab	DMM32GT	Plaque psoriasis	EA90.0	Approved	[6]
BI 655066	DMBH4FL	Chronic plaque psoriasis	EA90.0	Phase 3	[7]
MK-3222	DMQBF7O	Hairy cell leukaemia	2A82.2	Phase 3	[8]
Brazikumab	DM4NWPE	Crohn disease	DD70	Phase 3	[9]
ABP 654	DM0GXWT	Plaque psoriasis	EA90.0	Phase 3	[10]
CNT0-1959	DMOR8SY	Rheumatoid arthritis	FA20	Phase 2	[5]
AMG-139	DMEHOVF	Crohn disease	DD70	Phase 1	[11]

Drug(s) Targeting TAX transcriptionally-activated glycoprotein 1 (OX40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[12]
RG7888	DM2SWI8	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
Amlitelimab	DMKR3BQ	Asthma	CA23	Phase 2	[14]
MEDI6383	DM1YSMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
mRNA-2416	DMFTAWU	Lymphoma	2A80-2A86	Phase 1	[16]
SAR442970	DM3DHWE	Inflammation	1A00-CA43.1	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-23 (IL23)	TTC1GLB	IL23A_HUMAN	Replacement	[2]
Interleukin-36 gamma (IL36G)	TT8SLDN	IL36G_HUMAN	Replacement	[2]
TAX transcriptionally-activated glycoprotein 1 (OX40)	TTBW580	TNFL4_HUMAN	Replacement	[2]

References

• [1] ClinicalTrials.gov (NCT03739931) Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants With Advanced Malignancies. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [3] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [4] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [5] Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [7] Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7.
• [8] Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9.
• [9] Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.
• [10] Clinical pipeline report, company report or official report of Amgen
• [11] Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72.
• [12] Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68.
• [13] Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105.
• [14] OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753.
• [15] J Clin Oncol 33, 2015 (suppl; abstr 3056).
• [16] Clinical pipeline report, company report or official report of Moderna Therapeutics.
• [17] Clinical pipeline report, company report or official report of Sanofi